Management Team
Claes Glassell
President & Chief Executive Officer
Laurence M. Corash, M.D.
Senior Vice President & Chief Scientific Officer
Howard G. Ervin
Vice President, Legal Affairs
Kevin D. Green
Vice President, Finance and Chief Accounting Officer
William M. Greenman
Senior Vice President, Business Development & Marketing
Lori L. Roll
Vice President, Administration and Corporate Secretary
Claes Glassell - Mr. Glassell was appointed our President and Chief Executive Officer and was elected as a member of our Board in May, 2004. Mr. Glassell was President, Chief Operating Officer and a director of Cambrex Corporation from July 2001 until January 2003, and held management positions at Cambrex from 1994 to 2001, including Executive Vice President and Chief Operating Officer from 2000 until 2001 and Vice President and Managing Director of Cambrex Limited from 1994 until 2000. Previously, he was President and Chief Executive Officer of the Pharma Chemistry Business Area of Nobel Chemicals International AB and held various international management assignments with Berol in the United States, United Kingdom and Sweden. Mr. Glassell served on the Board of the Swedish Chemical Industry Association from 1993 to 1996 and was also a member of the Responsible Care Committee for the Swedish Chemical Industry Association. He currently serves on the boards of directors of CMC Biopharmaceuticals A/S, a contract manufacturing organization, and Cellartis AB, a biotechnology company.
Laurence M. Corash, M.D. - Dr. Corash, one of our co-founders, has served as a member of our Board since December 2002. He was appointed Chief Scientific Officer in 2009, and has held various medical positions within the company, including Chief Medical Officer, since 1994. Dr. Corash was a consultant to us from 1991 to 1994. He has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985 and was Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994, Dr. Corash was a consultant to the FDA Advisory Panel for Hematology Devices. He currently serves on the U.S. Health and Human Services' Advisory Committee on Blood Safety and Availability.
Howard G. Ervin - Mr. Ervin was appointed our Vice President, Legal Affairs in June 1999. From 1979 until 1999, he was a partner of the law firm of Cooley Godward LLP, formerly Cooley Godward Castro Huddleson & Tatum, practicing corporate and intellectual property law, and was an associate of that firm from 1973 until 1979.
Kevin D. Green - Mr. Green was appointed our Vice President, Finance and Chief Accounting Officer in 2009. Mr. Green served as our Senior Director of Finance and Controller from January 2006 until May 2009. From 2000 until 2006, Mr. Green held various financial management positions with Macromedia, Inc., a software company acquired by Adobe Systems in 2005, including Director of Finance and Assistant Controller. Prior to joining Macromedia, Mr. Green was a member of PricewaterhouseCoopers LLP in the Assurance and Business Advisory Services division. Mr. Green is a certified public accountant.
William M. Greenman - Mr. Greenman was appointed our Senior Vice President, Business Development & Marketing in November 2008. He had been President, Cerus Europe from September 2006 through October 2008. From 1999 until 2006, he was our Vice President, Business Development after returning to the Cerus from a brief time in the venture capital business. Prior to joining the Company in 1995 as Director of Business Devolopment, Mr. Greenman worked in various marketing and business development positions in Baxter's Biotech Division from 1991 to 1995.
Lori L. Roll - Ms. Roll was apointed our Vice President, Administration in 1999. From 1997 to 1999 she was our Director of Administration, and was our Controller from 1992 to 1997. Prior to joining Cerus, Ms. Roll spent six years working as a certified public accountant for Ernst & Young and also served as a Controller for two private companies.
|
